Funxional gets $12.5M for anti-inflammatory programs; Pozen snags $20M milestone

 @FierceBiotech: Teva tackles a Rituxan biosimilar. Report | Follow @FierceBiotech

 @JohnCFierce: So much for Pfizer's two-track approach to R&D, which always looked a tad uncomfortable to me. Now one R&D lord will rule them all. | Follow @JohnCFierce

> The UK's Funxional Therapeutics has raised $12.5 million in a Series B and plans to use the cash to further its anti-inflammatory therapies. The round was provided by Index Ventures and Novo AS along with new investor Ventech. Funxional release

> Covidien is selling its specialty chemical division to a private equity group for $280 million. The division makes ingredients for the biopharma business, among others. Report

> AstraZeneca paid Chapel Hill, NC-based Pozen a $20 million milestone it earned with the approval of Vimovo. Another $25 million will be due if Vimovo is approved in a major ex-US market. Release

> Irvine, CA-based Cobalis filed the forms necessary to emerge from bankruptcy. Cobalis release

> Immunomedics snagged a $5 million milestone from Nycomed, part of their deal on veltuzumab. Story

And Finally... A new study from the University of Rochester concludes that a high level of supposedly good cholesterol places a subgroup of patients at high risk for recurrent coronary events, such as chest pain, heart attack, and death. Report

Suggested Articles

The deal comes almost two years after Roche dropped the tumor microenvironment modulator after putting it through a clutch of early-phase studies.

The buzzy life sciences company Verily is looking to speed up COVID testing with a new lab based at its native South San Francisco.

Although Genfit canned its NASH program last month, it has been plugging away at a blood-based diagnostic for the liver disease.